−87JPY
−7.19 BJPY
12.77 BJPY
74.69 M
About NXERA PHARMA CO LTD
Sector
CEO
Chris Cargill
Headquarters
Tokyo
Website
Employees (FY)
350
Founded
2002
ISIN
JP3431300007
FIGI
BBG000Q25Z21
Sosei Group Corporation is a holding company primarily engaged in the biopharmaceutical business. The Company is mainly involved in the research, development and sale of pharmaceutical drugs, including NVA237 and QVA149, used for chronic obstructive pulmonary disease; SO - 1105, used for oral thrush. As of March 31, 2013, the Company had three consolidated subsidiaries.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 4565 is 1511 JPY — it has increased by 3.28% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on TSE exchange NXERA PHARMA CO LTD stocks are traded under the ticker 4565.
NXERA PHARMA CO LTD is going to release the next earnings report on May 9, 2024. Keep track of upcoming events with our Earnings Calendar.
4565 stock is 4.48% volatile and has beta coefficient of 0.65. Check out the list of the most volatile stocks — is NXERA PHARMA CO LTD there?
One year price forecast for NXERA PHARMA CO LTD has a max estimate of 3900 JPY and a min estimate of 1500 JPY.
4565 earnings for the last quarter are −59.92 JPY whereas the estimation was 30.67 JPY which accounts for −295.37% surprise. Estimated earnings for the next quarter are 3.72 JPY. See more details about NXERA PHARMA CO LTD earnings.
NXERA PHARMA CO LTD revenue for the last quarter amounts to 3.33 B JPY despite the estimated figure of 7.00 B JPY. In the next quarter revenue is expected to reach 6.27 B JPY.
Yes, you can track NXERA PHARMA CO LTD financials in yearly and quarterly reports right on TradingView.
4565 stock has fallen by 3.82% compared to the previous week, the month change is a 3.57% fall, over the last year NXERA PHARMA CO LTD has showed a 41.80% decrease.
4565 net income for the last quarter is −208.00 M JPY, while the quarter before that showed −4.93 B JPY of net income which accounts for 95.78% change. Track more NXERA PHARMA CO LTD financial stats to get the full picture.
Today NXERA PHARMA CO LTD has the market capitalization of 130.86 B, it has decreased by 0.51% over the last week.
No, 4565 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, 4565 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NXERA PHARMA CO LTD stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 18, 2024, the company has 350.00 employees. See our rating of the largest employees — is NXERA PHARMA CO LTD on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NXERA PHARMA CO LTD technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NXERA PHARMA CO LTD stock shows the sell signal. See more of NXERA PHARMA CO LTD technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on NXERA PHARMA CO LTD future price: according to them, 4565 price has a max estimate of 3900.00 JPY and a min estimate of 1500.00 JPY. Read a more detailed NXERA PHARMA CO LTD forecast: see what analysts think of NXERA PHARMA CO LTD and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NXERA PHARMA CO LTD EBITDA is −7.54 B JPY, and current EBITDA margin is −51.56%. See more stats in NXERA PHARMA CO LTD financial statements.